Innovation_China National Biotec Group Company Limited

Home>Innovation

R&D System

  • Development concept

    innovation
    coordination
    green
    openness
    sharing

    Development concept
  • Sci & tech policy

    Integration of basic research and applied research
    Integration of independent innovation and technology introduction
    Integration of technological and capital means

    Sci & tech policy
  • Scientific research positioning

    firmly grounded in market demand
    serves the nation’s needs
    and focuses on R&D
    Guided by market demand
    Targeting national needs

    Scientific research positioning
  • Vigorously expand open innovation

    China Biosciences unswervingly follows the open innovation path of scientific and technological cooperation and exchange at home and abroad. By introducing new products and advanced technologies at home and abroad, it closely integrates technical cooperation and exchanges with the cultivation of talent teams. In the introduction of new technologies and new products such as coagulation factors, we have conducted in-depth cooperation discussions and fruitful project exchanges with international companies and institutions.

    Vigorously expand open innovation

R&D Platforms

  • CNBG

    National Research Center

  • CNBG

    Six Specialized R&D Centers

  • CNBG

    Seven Technology Platforms

Strong expert team

CNBG has built a strong sci & tech innovation capacity with
a research team of over 1,000 members and a quality control team of 1,100-strong.
Among them are an academician of Chinese Academy of Engineering,
a top vaccine scientist enlisted in China’s National High-tech R&D Program (863 Program),
and 13 members of Chinese Pharmacopoeia Commission.

Academic Competence

The biological products arm of Chinese Preventive Medicine Association is affiliated with Beijing Institute of Biological Products Co., Ltd. It is a public-welfare organization for people working in the bio-product industry. Its membership includes 15 entities and nearly 350 individuals.

The vaccine committee of China Medicinal Biotech Association is also affiliated with Beijing Institute of Biological Products Co., Ltd. It brings together people working in the bio-product industry, implements China’s policies on sci & tech and public health, and serves scientists, sci & tech development, and national development.

The Chinese Journal of Microbiology and Immunology was founded in 1981. It is a scientific and technological journal under the Chinese Association for Science and Technology. It is one of the series of journals sponsored by the Chinese Medical Association. It is edited and published by the Beijing Institute of Biological Products. It aims to reflect the major progress of scientific research in microbiology and immunology in my country, provide information services for this professional scientific researcher, promote academic exchanges at home and abroad, and promote the development of this discipline. The Chinese Journal of Microbiology and Immunology mainly publishes research papers, briefings and reviews on medical microbiology and immunology, and reports on domestic and foreign academic developments. There are bacteriology, virology, molecular microbiology, basic immunology, clinical microbiology, clinical immunology, immune genetics, tumor immunity. Chinese medicine and immunity, immunology technology, detection technology and other columns.

《Chinese Journal of Biological Products》 is the only domestic professional academic journal for biological products that reports the major achievements in the research and development of biological products in my country and the latest developments at home and abroad. It is headed by the Ministry of Health, China Preventive Medicine Association and China National Pharmaceutical Group Corporation Changchun Biological Products Sponsored by the Institute. It mainly publishes academic articles on the research, production, use and quality control of biological products and biotechnology products, such as preventive medicine, immunology, microbiology, biochemistry, epidemiology, clinical medicine, etc. Pay attention to academic, cutting-edge and practicality when selecting submissions. Give priority to reporting fund projects and articles on various fund-sponsored topics, and take appropriate care of remote areas and grassroots units. The Chinese Journal of Biological Products has columns for basic research, preventive products, therapeutic products, diagnostic products, experimental technology and methods, clinical observations, research briefs, reviews, reviews, conference news, news trends, etc.

《International Journal of Biologicals》It belongs to the series of journals of the Chinese Medical Association. It is a national academic journal sponsored by the National Health and Family Planning Commission, the Chinese Medical Association and the Shanghai Institute of Biological Products Co., Ltd. Founded in 1978, this journal is the first professional journal of biological sciences published in my country and has an important influence in the domestic biological sciences field. This journal focuses on introducing new developments, new trends, new technologies and new achievements in the field of biological products at home and abroad. The content mainly includes virus, bacteria and other pathogen vaccines, tumor vaccines and other non-infectious disease vaccines, microecological preparations, antitoxins and antisera, blood products, cytokines, monoclonal antibodies, immunotherapeutic products, diagnostic products and biotechnology products , Development, production, verification and clinical application. The readers are mainly scientific and technical personnel engaged in the production, research and application of biological products, health and epidemic prevention workers, clinicians and teachers and students of medical schools. This journal has columns for reviews, treatises, short treatises, case reports, introductions to international conferences, introductions to international institutions, standards and guidelines.

《Progress in Microbiology and Immunology》 was founded in 1973. It is headed by China Biotechnology Co., Ltd., sponsored by Lanzhou Institute of Biological Products Co., Ltd., and one of the series of journals of the Chinese Preventive Medicine Association. It is a statistical source journal of China's scientific and technological papers (core journals of China's science and technology), a statistical source journal of the Comprehensive Evaluation Database of Chinese Academic Journals (CAJCED), a statistical source journal of "Chinese Academic Journal Impact Factor Annual Report", a journal included in the China Journal Full-text Database (CJFD), USA Journals included in Chemical Abstracts (CA), full-text journals included in CNKI, Wanfang Database, and Weipu Database. The purpose of this journal is to report new theories, new developments, new methods, new technologies, new results, etc. in microbiology, immunology and related fields at home and abroad, disseminate scientific and technological information, promote academic exchanges and applications, and serve microbiology, immunology, and Services for the development and progress of careers in related fields. The main columns include expert forums, treatises, reviews, abstracts, and literature quick reviews. Pay attention to academic, cutting-edge and practicality when selecting submissions. Give priority to reporting on fund projects and articles on various fund-sponsored topics, and take appropriate care of remote units and grassroots units. "Progress in Microbiology and Immunology" won the 2008 Excellent Journal of Gansu Province, 2009-2010 Excellent Journal Progress Award of the Chinese Preventive Medicine Association Series, and 2013-2014 Chinese Preventive Medicine Association Series Journal Editor Quality Award.

Tech Investment & Innovation

  • Pay attention to scientific research investment

    From 2010 through 2019, CNBG invested a total of 7.4 billion yuan in science and technology, averaging 740 million yuan a year. In 2019, the company’s science and technology investment ratio reached 13 percent, higher than the average level among domestic industry players.

  • Rich innovation

    Since the first strain of penicillin in China was isolated in 1942 and achieved a zero breakthrough in China’s biological products, the company has successfully developed smallpox vaccines, cholera vaccines, typhoid vaccines, measles vaccines, hepatitis A vaccines, hepatitis B vaccines, and oral rotavirus live vaccines. Biological products such as vaccines, polio vaccines, type A botulinum products, healthy human plasma albumin and blood coagulation factor VIII, cover almost all of China's biological products.

  • Undertake a number of national projects

    From 2010 to 2018, Sinopharm and its subsidiaries undertook a total of 140 national projects of various kinds, and received 630.578 million yuan from the central government and 601.564 million yuan from the central government. Among them, the 863 plan, 6 science and technology support plans, 18 major new drug creation special projects, 9 major infectious diseases special projects, 1 international cooperation project of the Ministry of Science and Technology, 1 emergency special project of the Ministry of Science and Technology, 10 state-owned capital projects, and protein drugs of the Development and Reform Commission There are 4 special projects, 2 other ministries and commissions, and 89 provincial and municipal projects.